Soleno Therapeutics Inc

### Capital Structure and Liquidity Soleno Therapeutics Inc maintains a strong liquidity position, with a current ratio of 5.8, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $70.1 million, which is a substantial portion of its total assets of $563.8 million. The company's long-term debt is relatively low at $49.9 million, and its debt-to-equity ratio is 0.11, suggesting a conservative capital structure. The free cash flow of $22.8 million further supports the company's liquidity and financial flexibility.

### Profitability and Returns The company's profitability is reflected in its gross profit of $187.7 million and operating income of $9.4 million, with a net income of $20.9 million. The return on equity (ROE) is 4.64%, and the return on assets (ROA) is 3.71%, which are in line with the industry's preferred metrics for biotechnology firms. These returns suggest that the company is generating reasonable returns on its equity and assets, though there is room for improvement to outperform the industry median.

### Segments and Geographic Exposure Soleno Therapeutics Inc operates as a single business segment, focusing on the development and commercialization of pharmaceutical products. The company's revenue is primarily derived from the United States, with no significant international exposure disclosed in the available data. This concentration in a single geographic market may pose a risk if the U.S. market experiences regulatory or economic challenges.

### Growth Trajectory The company's revenue for the latest period is $190.4 million, and while there are no specific growth projections provided, the company's strong liquidity and positive cash flows suggest a stable financial position. The company's capital expenditure is minimal at -$73,000, indicating a low level of investment in physical assets, which is typical for a biotechnology firm that may focus more on R&D and product development.

### Risk Factors The company's risk assessment indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The ESG score of 20.50 and a grade of D+ suggest that the company has room for improvement in its environmental, social, and governance practices. The low environment pillar score of 0 and the governance pillar score of 24.17 highlight areas where the company could enhance its sustainability and corporate governance.

### Recent Events The company's recent financial performance is reflected in its last actual EPS of $0.39 and revenue of $190.4 million. There are no specific recent events or filings mentioned that would significantly impact the company's operations or financial position.